Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor
Eli Lilly (LLY) hit a record high, raising its 2026 revenue forecast to $91-$92B, lifting its market value to $1.1T. Macro investor Jordi Visser predicts Lilly will become the world's most valuable company due to steady healthcare spending and AI investment. Analysts expect Nvidia's (NVDA) earnings per share to quadruple in three years, making Lilly's potential surpass a significant challenge.
How this was made
The 30-second read
Why it matters
The record high and guidance raise may trigger momentum buying and attract attention from growth‑focused funds.
Market read
Lilly’s guidance upgrade is a high‑impact, large‑cap event that could influence both sector and broader market sentiment.
What to watch
Potential regulatory pressure on drug pricing and competition in the GLP‑1 space could temper upside.
Background
The article quotes macro investor Jordi Visser and references a podcast with Anthony Pompliano, framing the guidance lift as a catalyst for a potential shift in the hierarchy of the world’s most valuable companies.
Ticker impact
Eli Lilly raised its 2026 revenue forecast to $91‑$92 billion, sending the stock to a record high and lifting its market value to about $1.1 trillion.
likely upward pressure as investors price in higher revenue expectations
The new multi‑billion‑dollar revenue outlook is a material, first‑time disclosure for a trillion‑dollar market‑cap company.
Market effects
Strengthens the broader healthcare/pharma sector outlook as demand for GLP‑1 drugs appears resilient.
U.S. market may see a modest lift in biotech indices.
Highlights the growing importance of recurring healthcare spend in global growth narratives.
Counterpoint
If the revenue boost is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyEli Lilly
Pharmaceutical company that announced the revenue forecast increase.
- individualJordi Visser
Macro investor providing the bullish thesis.
